Immunome price target lowered to $25 from $35 at Guggenheim

Guggenheim analyst Michael Schmidt lowered the firm’s price target on Immunome (IMNM) to $25 from $35 and keeps a Buy rating on the shares after updating the firm’s model to reflect Q4 results. The firm cites stock dilution following the recent financing in Q1, partially offset by incrementally increased odds of success seen for IM-1021 following positive data from Merck’s (MRK) MK-2140 program in December for its revised price target.